证券代码：003017 股票简称：大洋生物 公告编号：2025-085 浙江大洋生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、本公告日前十二个月公司使用闲置募集资金进行现金管理的情况 截至本公告日，公司及子公司使用闲置募集资金进行现金管理尚未到期的金 额为人民币 11,000.00 万元，未超出公司第六届董事会第五次会议关于使用闲置募 集资金进行现金管理的授权额度。截至本公告日，公司使用闲置募集资金进行现 金管理具体情况如下： | | | | | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 申 | 签 | | | | 产 | | 起 | | 到 | | | 是 | | 序 | 购 | 约 | | | | 品 | 认购金 | | 息 | | 期 | 预期年化 | | | 收 | | | 否 | 投资 | | | | | | | | | | | | ...

Core Viewpoint - The company has announced the continued use of idle raised funds for cash management, aiming to enhance fund utilization efficiency while ensuring that the funds required for project construction are not affected [2][4]. Group 1: Cash Management Progress - The company has redeemed a financial product purchased with idle raised funds, amounting to 17 million yuan, and has earned a return of 193,900 yuan, which has been fully deposited into the special account for raised funds [3]. - The company plans to use up to 140 million yuan of idle raised funds for cash management within 12 months from the board's approval date [2][4]. Group 2: Financial Product Details - The company has invested in a structured deposit product with a principal of 17 million yuan, with an expected annualized return of 1.25% to 2.50% [3][5]. - As of the announcement date, the company and its subsidiaries have 120 million yuan of idle raised funds in cash management that have not yet matured, which is within the authorized limit set by the board [5]. Group 3: Impact on the Company - The cash management of idle raised funds is expected to improve fund efficiency and generate investment returns for the company and its shareholders, without impacting the construction of fundraising projects [4][5].